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Abstract
Background: Recent systematic reviews on psychological therapies of fibromyalgia syndrome (FMS) did not
consider hypnosis/guided imagery (H/GI). Therefore we performed a systematic review with meta-analysis of the
efficacy of H/GI in FMS.
Methods: We screened http://ClinicalTrials.gov, Cochrane Library, MEDLINE, PsycINFO and SCOPUS (through
December 2010). (Quasi-) randomized controlled trials (CTs) comparing H/GI with controls were analyzed.
Outcomes were pain, sleep, fatigue, depressed mood and health-related quality of life (HRQOL). Effects were
summarized using standardized mean differences (SMD).
Results: Six CTs with 239 subjects with a median of 9 (range 7-12) H/GI-sessions were analysed. The median
number of patients in the H/GI groups was 20 (range 8-26). Three studies performed follow-ups. H/GI reduced pain
compared to controls at final treatment (SMD -1.17 [95% CI -2.21, -0.13]; p = 0.03). H/GI did not reduce limitations
of HRQOL at final treatment (SMD -0.90 [95% CI -2.55, 0.76]; p = 0.29) compared to controls. Effect sizes on fatigue,
sleep and depressed mood at final treatment and follow-up and on pain and HRQOL at follow-up were not
calculated because of limited data available. The significant effect on pain at final treatment was associated with
low methodological and low treatment quality.
Conclusion: Further studies with better treatment quality and adequate methodological quality assessing all key
domains of FMS are necessary to clarify the efficacy of H/GI in FMS.
Background
The key symptoms of fibromyalgia syndrome (FMS) are
chronic widespread pain, fatigue (physical exhaustion
and cognitive disturbances) and non-restorative sleep
[1]. Besides these symptoms global multidimensional
function ( = health related quality of life [HRQOL]) and
tenderness are regarded to be the key domains of thera-
peutic trials in FMS [2].
Patients with FMS use a lot of pharmacological and
non-pharmacological therapies resulting in high costs of
health services [3]. Pharmacological and physical thera-
pies are more frequently used than psychological treat-
ments. Although hypnotic pain relief is among the
oldest treatments for pain, interest in hypnotic
treatments for chronic pain appears to rise only in the
last decade [4]. In an internet survey only 3% of the
respondents reported to use hypnosis to relieve FMS-
symptoms [5].
A hypnotic procedure is used to encourage and evalu-
ate responses to suggestions. When using hypnosis, one
person (the subject) is guided by another (the hypnotist)
to respond to suggestions [6]. The suggestions can be
direct (traditional hypnosis) or permissive (Ericksonian
hypnosis). Imagery is defined as a dynamic, psychophy-
siologic process in which a person imagines and experi-
ences an internal reality in the absence of external
stimuli. These images can be initiated by the patient or
guided by a therapist (guided imagery) [7]. Both techni-
ques aim to promote changes in subjective experience,
alterations in perception, sensation, emotion, thought or
behaviour by suggestion and/or imagination [6,7].
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pain syndromes included only one study with hypnosis
in FMS [8]. A recent systematic review on the efficacy
of psychological therapies in FMS did not include stu-
dies with hypnosis/guided imagery [9]. Therefore we
saw the need to perform a systematic review with meta-
analysis of the efficacy of hypnosis/guided imagery com-
pared to control therapies to reduce the key symptoms
of FMS-patients of any age.
Methods
The review was performed according to the PRISMA-
statement (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses [10] and the recommenda-
tions of the Cochrane Collaboration [11].
Protocol
Methods of analysis and inclusion criteria were specified
in advance. We used the review protocol of our sys-
tematic review on cognitive behavioral therapies in FMS
[12].
Eligibility criteria
Types of interventions
Studies with hypnosis and guided imagery as an active
treatment of primary interest for FMS were included.
Hypnosis/guided imagery should use pain-related and/or
pain- addressed suggestions and/or images. Studies with
relaxation only (without trance induction or without the
use of imagination) or with the combination of hypnosis
with a defined pharmacological therapy as an active
treatment of primary interest were excluded. Experi-
mental studies (single session) with hypnosis/guided
imagery were excluded.
Types of studies
A controlled design (controlled trials = CTs) was
demanded. In case of multiple control groups we prede-
fined the following order for comparison: Cognitive
intervention (nonspecific elements of hypnosis/guided
imagery such as education, emotional support, pure
relaxation, suggestions without induction of hypnotic
trance), treatment as usual, waiting list, active therapy
(any defined pharmacological or non-pharmacological
intervention other than hypnosis/guided imagery). The
number of patients in each study arm should be > 5.
The studies should be available as a full publication in a
peer reviewed science journal.
Types of participants
Patients diagnosed with FMS based on defined criteria
and of any age were included.
Types of outcomes measures
Studies should assess at least one key domain of FMS
(pain, sleep, fatigue, HRQOL) [2]. Depressed mood was
chosen for secondary outcome because depressive
symptoms frequently occur in FMS-patients [1] and
improving emotional status is one main target of hypno-
sis/guided imagery [6,7].
Data sources and searches
The electronic bibliographic databases screened
included http://ClinicalTrials.gov, Cochrane Central
Register of Controlled Trials (CENTRAL), MEDLINE,
PsycINFO and SCOPUS (through December 30, 2010).
The search strategy for MEDLINE was as follows:
(("Hypnosis"[Mesh] OR “Imagery (Psychotherapy)"[-
Mesh])) AND “Fibromyalgia"[Mesh] AND ((clinical
[Title/Abstract] AND trial[Title/Abstract]) OR clinical
trials[MeSH Terms] OR clinical trial[Publication
Type] OR random*[Title/Abstract] OR random
allocation[MeSH Terms] OR therapeutic use[MeSH
Subheading])
The search strategy was adapted for the other data-
bases. No language restrictions were made. In addition,
reference sections of original studies were screened
manually.
Study selection
Two authors independently screened the titles and
abstracts of potentially eligible studies identified by the
search strategy detailed above (NF, PK). The full text
articles were then examined independently by two
authors to determine if they met the inclusion criteria
(KB, WH).
Data collection process
Two authors independently extracted the data using
standard extraction forms (KB, NF). Discrepancies were
rechecked and consensus achieved by discussion. If
needed a third author reviewed the data to reach a con-
sensus (WH).
We contacted all trial authors for further details of
their methodology. The requests were answered by
four authors. Where means or standard deviations
(SDs) were missing, attempts were made to obtain
these data through contacting four trial authors. Addi-
tional data were provided by three authors. Where SDs
were not available from trial authors, they were calcu-
lated from t-values, confidence intervals or standard
errors, where reported in articles. If these data were
not available, the SD was substituted by the mean of
the SDs of studies available which used the same out-
come scale [12].
Data items
The data of study setting, participants, inclusion and
exclusion criteria, interventions, cotherapies, side effects
reported and outcomes used for meta-analysis are listed
in tables 1 and 2.
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Page 2 of 11Table 1 Main characteristics of controlled studies with hypnosis/guided imagery in fibromyalgia syndrome
Author
Country Year
Setting
Referral
[Reference]
Mean
age
(years)
Women
%
Exclusion criteria Diagnosis
of FMS
Total study population
Screened/randomized
N (%) Total/
Completing therapy N
(%)
Treatment
group Total/
Completing
therapy N(%)
Control
group Total/
Completing
therapy N
(%)
Outcomes
used for
metaanalysis
Alvarez
2007
Mexico
University
Hospital
Rheumatology
clinics
[23]
44 yrs
100%
women
100%
Mexican
mez-
stizos
No other significant painful or
chronic comorbidities
ACR 50/43
(86)
43/11 (26)
20/7 *
(35)
23/4*
(17)
Pain VAS 0-
100 *
Fatigue NA
Sleep NA
Depressed
mood NA
HRQOL: FIQ
total *
No follow-
up
Castel
2009
Spain
University
Hospital
Pain clinic
[24]
44 yrs
95%
women
100%
white
Other severe chronic pain
condition; severe
psychopathology; moderate
cognitive impairment;pending
litigation
ACR
18-60 years
At least 6
years
education
NR/47
35/32 (91)
17/16
(94)
18/16 (89) Pain NRS 0-
10
Fatigue NA
Sleep NA
Depressed
mood NA
HRQOL FIQ
total
No follow-up
Grøndhal
2008
Norway
General
practice
General
practices
[25]
23-54 yrs
75%
women
100%
white
Organic diseases
Severe psychiatric disorder
Clinical
diagnosis of
chronic
widespread
pain
18/16
(89)
16/12 (75)
8/7
(88)
8/5 (63) Pain NRS 1-7*
(a)
Fatigue NRS
1-7 * (a)
Sleep NA
Depressed
mood NRS 1-
7 * (a)
HRQOL NA
1 year
without
control
Haanen
1991
Netherlands
Rheumatology
department
regional
hospital
NR
[26]
45 yrs
95%
women
NR
Organic diseases Smythe
Normal
blood test
NP
40/37 (93)
20/17
(85)
20/20 (100) Pain VAS 0-
10 **
Sleep VAS 0-
10 **
Fatigue VAS
0-10 ***
Depressed
mood NA
HRQOL NA
12 weeks
Menziers
2006
USA
University
hospital
Physicians and
clinics
[27]
50 yrs
98%
women
90%
white
Inflammatory rheumatic
disease
Major communicative disorder
Clinical
diagnosis
Age > 18
FIQ-Total >
20
MMSE score
>2 5
NP
48/NP
24/NR 24/NR Pain VAS 0-
10
Fatigue: NA
Sleep NA
Depressed
mood NA
HRQOL FIQ
total
4 weeks
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To ascertain the methodological quality of the eligible
studies, two authors independently (KB, NF) rated eligi-
ble trials using a scale developed specifically for assessing
the quality of psychological treatments for chronic pain
[13]. Discrepancies were rechecked and consensus
achieved by discussion. If needed a third author reviewed
the data to reach a consensus (WH). The Quality Rating
Scale is comprised of an overall quality score (0-35) con-
sisting of two subscales. A treatment quality subscale (0-
9) covers stated rationale for treatment, manualization,
therapist training and patient engagement. Patient
engagement was defined by checking for trance phenom-
ena during hypnosis and/or execution of homework
audiotape training. A design and methods quality sub-
scale (0-26) covers inclusion/exclusion criteria, attrition,
sample description, minimization of bias (randomisation
method, allocation bias, blinding of assessment, equality
for treatment expectations), selection of outcomes, length
of follow-up, adequacy of statistical analyses (a priori
power calculation, sufficient sample size, adequate data
analysis and summary statistics, intention to treat analy-
sis) and choice of control. We assumed a sample size of
at least 10 per treatment arm to be sufficient. We defined
scores 0-2 to indicate a poor, scores 3-5 an average and
scores 6-9 an excellent treatment quality and scores 0-12
indicating a low, scores 13-19 a medium and scores > 19
a high methodological quality. Interrater reliability was
calculated for both subscales by intra-class correlation
coefficients (ICC).
Summary measures
Meta-analyses were conducted using RevMan Analyses
software (RevMan 5.0.24) of the Cochrane collaboration
[14]. Standardized mean differences (SMD) were calcu-
lated by means and SDs for each intervention. Examina-
tion of the combined results was performed by a
random effects model (inverse variance method),
because this model is more conservative than the fixed-
effects model and incorporates both within-study and
b e t w e e n - s t u d yv a r i a n c e[ 1 5 ] .S M Du s e di nC o c h r a n e
reviews is the effect size known as Hedges (adjusted) g.
We used Cohen’s categories to evaluate the magnitude
of the effect size, calculated by SMD, with g > 0.2-0.5 =
small effect size, g > 0.5-0.8 = medium effect size, g >
0.8 = large effect size [16].
Planned methods of analysis
Heterogeneity was tested using the I² statistics with I²
values above 50% indicate substantial heterogeneity.
Tau² was used to determine how much heterogeneity
was explained by subgroup differences [11].
Risk of bias across studies
Potential publication bias (i.e. the association of publica-
tion probability with the statistical significance of study
results) was investigated the Egger test, in which the
standardized effect size (effect size calculated by stan-
dard error) is regressed on precision (inverse of standard
error). The intercept value is an estimate of asymmetry
of funnel plot. Positive values (> 0) indicate higher levels
of effect size in studies with smaller sample sizes [17].
Additional analyses
Subgroup and sensitivity analysis
If there were at least three studies available, subgroup
analyses were prespecified for type of psychological ther-
apy (hypnosis and guided imagery; hypnosis/guided ima-
gery with and without home training with audiotapes)
and type of control group. These subgroup analyses
were also used to examine potential sources of clinical
heterogeneity.
We decided post-hoc to perform a sensitivity analysis
of studies without calculated values (median instead of
mean; SD calculated from other studies; adjusting for
baseline values).
Metaregression analyses
We a priori decided to metaregress SMDs with the
treatment and methodological quality score for potential
sources of heterogeneity. We post - hoc decided to
Table 1 Main characteristics of controlled studies with hypnosis/guided imagery in fibromyalgia syndrome (Continued)
Rucco
1995
Italy
Regional
hospital
[28]
38 yrs
100%
women
NR
Analgesic medication
Major psychiatric disorder
ACR criteria
Normal
blood tests
NP
53/35 (66)
26/24
(92)
27/11
(41)
Pain VAS 0-
10
Fatigue NA
Sleep VAS 0-
10
Depressed
mood NA
HRQOL NA
No follow up
Abbreviations: * Data provided on request; (a) adjusted for baseline values; ** Median used for analysis; Standard deviation not reported; calculated from mean
of other trials; *** Median not entered into meta-analysis; no calculation of standard deviation from other trials possible
FIQ = Fibromyalgia Impact questionnaire; HRQOL = Health-related quality of life; NA = Not assessed; NP = Not provided on request; NRS = Numeric Rating Scale;
VAS = Visual Analogue Scale;
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of the studies. Meta-regression was performed using the
mixed effects model. Tau² variance was calculated by
the method of unrestricted maximum likelihood by
Comprehensive Metaanalysis software [18].
Results
Results of search
The search of literature yielded 57 hits. After excluding
studies based on information presented in study
abstracts, nine complete study reports were considered
Table 2 Details on therapeutic techniques and co-therapies of the studies analysed
Author
(Reference)
Types and duration of treatment in hypnosis/
guided imagery group
Types and duration of treatment in controls Comedication allowed
Other cotherapies
Side effects reported
Alvarez [23] Ericksonian hypnosis, individual:
Induction NR; 5 techniques could be used for
utilisation: transformation of pain or emotion;
metaphors; dissociation of pain; perceptions of other
body sensations; pleasant imagery; posthypnotic
suggestions of negative hallucinations and amnesia of
pain
60 min, 6- 8 sessions over 6 months
Total: 420 min
Cognitive intervention: Sham hypnosis, individual:
General issues talking with the therapist; physical
sign check list to verify that the patients were not in
hypnotic trance *
60 min, 6- 8 sessions over 6 months
Total: 420 min
NSAIDs, amitriptyline,
physiotherapy kept
stable during study *
NR
4/20 with hypnosis drop
out lack of efficacy
7/20 with sham
hypnosis drop out lack
of efficacy
Castel [24] CBT plus standardised hypnosis; group: Induction by
fixation and palpepral catalepsy; deepening by
visualisation; suggestion of an analgesic stream
eliminating pain and creating feelings of well-being;
posthypnotic suggestions NR
90 min (of which 20 min hypnosis) for 12 weeks;
daily home training with audiocasettes recommended
Total: 1080 min
Active control: CBT; group. Information in FMS,
cognitive restructuring, assertiveness training,
behavioral goal setting, problems solving;
90 min (of which 20 min relaxation training) for 12
weeks
Total: 1080 min
Study arm treatment as usual not used for
comparison
Analgesics,
antidepressants,
sedatives, myorelaxants
NR
NR
Grøndahl
[25]
Standardised hypnosis, individual: Relaxation,
visualisation of positive body experience; suggestion
of increase of self-efficacy, posthypnotic suggestions
NR
10 wks, 1/week, 30 min
Total: 300 min
Treatment as usual: Medication and physiotherapy or
chiropractic therapy
Total Min NR
Medication and
physiotherapy or
chiropractic therapy
NR
NR
Haanen
[26]
Standardised hypnosis, individual and daily
audiocassette: Induction by arm levitation;
suggestions of ego-strengthening, pain control and
improvement sleep; posthypnotic suggestions NR
8 × 60 min over 3 months; daily home training
Total: 360 min (without home training)
Active control
Physical therapy: Massage and muscle relaxation 1-2
h/week over 12 weeks
Total: 720-1440 min
Only paracetamol
allowed
NR
NR
Menziers
[27]
Standardised guided imagery, indvidual, at home:
3 standardised audio cassettes: Relaxation, signal
breath to elicit relaxation; imagination of pleasant
scene; suggestions of feeling of well-being and
actions and behaviors free of FMS-symptoms
30 min daily for 6 weeks recommended
Total: Median of 44 (range 37-136) exercises
Treatment as usual
Total Min NR
Treatment as usual
NR
NR
Rucco [28] Ericksonian hypnosis, individual: Metaphors for
induction, Utilisation: identification and solution of
intrapsychic conflicts; posthypnotic suggestions NR
Frequency of sessions individualised over 6 months
Active control: Autogenic training in group
Practice: 8 weeks, twice a week, 15 min;
Recommendation of daily practice over 6 months
Total: 240 min
No comedication
allowed
NR
NR
* Details provided on request; NR = Not reported and not provided on request
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mental guided imagery [19,20], one study with experi-
mental hypnosis [21] and one study with two patients in
each treatment arm [22] were excluded. Finally six stu-
dies were included in qualitative analysis [23-28] (see
figure 1).
Study characteristics
Setting, referral and exclusion criteria
Four studies were conducted in Europe and one study
each in USA and Mexico. Patients were recruited by
registers of hospitals, referral (general practitioner, rheu-
matologist, departments of hospitals) and local self-help
groups. Five studies were conducted in hospitals (uni-
versity, district hospital) and one study in a general
practitioner office. All studies were single center based.
One study did not report the exclusion criteria. All
other studies included only adult patients (> 18 years)
and excluded patients with major somatic and/or mental
diseases. One study excluded patients with litigation/
pension associated with FMS and one study excluded
patients who were taken analgetisic medication (see
table 1).
FMS was diagnosed in three studies by the criteria of
the American College of Rheumatology [29], in one
study by the Smythe criteria [30] and in two studies by
clinical (not further specified) criteria. No study
reported the frequency of mental disorders.
Participants
Two studies reported the percentage of persons
screened who were subsequently randomised with a
median of 87 (range 86-89) %. The median of the
mean age of the participants was 44 (range 38- 50)
years. The median of the percentage of women was 96
(range 75-100) %. Six studies reported the race of the
patients. The median of the percentage of Caucasians
was 95 (0-100) %. One Mexican study included 100%
mestizos.
The median of the patients under hypnosis/guided
imagery in the studies was 20 (range 8-26) and of con-
trols was 22 (range 8-27) (see table 1). The total num-
ber of patients with hypnosis/guided imagery was 115
of which a median percentage of 88 (range 35-94) %
completed therapy. The total number of patients in the
control groups was 124 of which a median percentage
of 63 (range 17-100) completed therapy (z = -0.5, p =
0.7).
Interventions
Five studies offered hypnosis: Three studies with direct
hypnosis of which one was combined with cognitive-
behavioral therapy, two studies with indirect [Erickso-
nian] hypnosis). One study offered guided imagery. Four
studies with hypnosis explicetly mentioned the use of
mental images. All but one study used suggestions and/
or images which were directly addressed to the pain
experience. All studies used pain-related suggestions.
The study with guided imagery used suggestions. Hyp-
nosis/guided imagery were delivered in five studies as
individual therapy and in one study as group therapy.
Hypnosis/guided imagery were offered in five studies by
face-to face (life), in one study by audiotapes. Three stu-
dies recommended daily training at home with audio-
tapes. The median number of sessions with a therapist
was nine (range 7-12). The median of hypnosis/guided
imagery delivered by a therapist was 390 (range 300-
1080 min). The number of sessions in one trial with
Ericksonian hypnosis was individualized. Median and
range of the number of sessions of this study were not
reported.
In one study controls received a cognitive intervention
(sham hypnosis), in three studies active therapy (cogni-
tive behavioral therapy, physical therapy, autogenic
training) and in two studies treatment as usual (see
table 2).
Three studies performed a follow-up of which one
(after one year) was without controls because the con-
trols had switched to hypnotherapy. The median of fol-
low-up of the other two studies was 8 (range 4-12)
weeks.
Outcomes
Pain was assessed in all studies, sleep in two and fatigue
and depressed mood in one study each by visual or
numeric scales. HRQOL was assessed in three studies
by the Fibromyalgia Impact Questionnaire. Two authors
provided additional outcomes on request. One author
did not provide the means and standard deviations of
his study in which medians and ranges had been pre-
sented (see table 1).
No study assessed predefined response rates (e.g. per-
centage of patients with 30% pain reduction). Only one
study reported the number of patients who dropped out
because of lack of efficacy. No study reported on side
effects.
Quality ratings of trials
Three authors provided additional information on meth-
ods on request (see tables 3 and 4). The ICC using
absolute agreement for the two raters was 0.96 (F = 3.4)
for the treatment quality and 0.97 (F = 3.4) for the
design quality subscale.
The median of the treatment quality score was 6
( r a n g e1 - 9 ) .O n es t u d yh a dap o o r ,t w os t u d i e sh a da
medium and three studies had an excellent treatment
quality score (see table 3).
The median of the methodological quality score was
16 (range 10-20). One study had a poor, four studies
had a medium and one study had an excellent methodo-
logical quality score (see table 4).
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Overall meta-analysis
The means, SDs, sample sizes and effect estimates at
posttreatment and at follow-up of the remaining eight
studies can be seen in the forest plots (see figure 2).
The data are reported as follows: (SMD [95% Confi-
dence interval]). Hypnosis/guided imagery reduced
pain (-1.17 [-2.21, -0.13]) compared to controls at
final treatment. Hypnosis/guided imagery did not
reduce the limitations of HRQOL -0.90 [-2.55, 0.76]
compared to controls at final treatment. Based on
Cohens’ categories the effect on pain at final treat-
ment was large.
Because of limited data available effect sizes on sleep,
fatigue and depressed mood were not calculated at final
treatment and not for all outcomes at follow-up (see
table 1). Two studies reported that hypnosis was super-
ior to controls in reducing sleep disturbances at final
treatment [26,28]. Two studies reported that hypnosis/
guided imagery was superior to controls in reducing
pain at follow-up [26,27]. One study reported that hyp-
nosis was superior to controls in reducing fatigue at
final treatment and at follow-up [26]. In one study
hypnosis was not superior to therapy as usual at post-
treatment in reducing depressed mood [25].
Potential publication bias
In the Egger’s test the intercept of the effect size on pain
was 0.13 (95% CI -8.7, 9.0) with t = 0.03 (two-tailed p =
0.97) and thus not indicative for a publication bias.
Risk of bias across studies and subgroup analysis
There was substantial heterogeneity in the outcome pain
at final treatment (see table 5). Subgroup analyses were
not calculated, because < 4 studies for subgroups were
available.
Sensitivity analysis
The effect on pain at final treatment was no more sig-
nificant after removing the two studies in which some
values were calculated by the authors of this review
(-1.38 [-2.95, 0.20]; I² = 92%; p = 0.09).
Metaregression analyses
Simple linear regressions showed that treatment quality
(ß = -3.6, p < 0.0001), and methodological quality (ß =
-8.7, p < 0.0001)) were significantly negatively associated
with the effect size on pain at final treatment. Sample
size was not associated with the effects size on pain at
final treatment (ß = 0.42, p = 0.65).
Search of electronic databases 
                   2 ClinicalTrials.Gov  
 2 CENTRAL   
13 Embase 
                  16 Medline 
                  21 PsychInfo 
3 of additional records identified by 
other searches 
10 records after duplicates removed 
47 records screened  38  records excluded 
9 full-text articles assessed for 
egilibility 
3 Excluded: 
1 with experimental hypnosis 
1 with experimental guided 
imagery 
1 with treatment arm <5 
6 studies included in 
qualitative synthesis and 
meta-analysis 
Figure 1 PRISMA flow diagram.
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Summary of evidence
The evidence of the efficacy of hypnosis/guided imagery
to reduce pain at final treatment was not robust against
risks of methodological bias and was associated with
low methodological study quality.
Applicability of evidence
The study settings of all levels of care and the study
samples with a preponderance of middle aged women
are representative for clinical FMS populations in Amer-
ica and Europe.
Agreements with other systematic reviews
The German FMS guideline group concluded by a quali-
tative systematic review that hypnosis/guided imagery
was superior to controls in reducing pain, sleep
disturbances and fatigue [31]. Our update of the litera-
ture with inclusion of recently published studies and
quantitative analysis of outcomes supports that hypno-
sis/guided imagery was effective in relieving pain and
sleep problems. A meta-analytic confirmation of the effi-
cacy on fatigue was not possible because of the metho-
dological problems outlined above. In contrast to a
recent qualitative review on psychological therapies in
FMS which described “mild effects” of hypnosis/guided
imagery on FMS-symptoms [32] we found large effects
on pain and medium effects sizes on sleep at final treat-
ment and at follow-up.
Limitations
We decided to pool studies with hypnosis and guided
imagery because of their similaries regarding theoretical
Table 3 Treatment quality of studies with guided imagery/hypnosis in FMS
Author
(Reference)
Treatment
content
Treat-ment
duration
Manualisa-tion of
treatment
Adherence to
manual
Therapist
training
Client
engagement
Sum
Alvarez [23] Adequate (2) Reported (1) Partial (1) * Partial (1) * Adequate (2) * Adequate (1)* 8
Castel [24] Adequate (2) Reported (1) Partial (1) Inadequate (0) Inadequate (0) Inadequate (0) 4
Grøndahl [25] Adequate (2) * Reported (1) Adequate (2) * Partial (1) * Adequate (2) * Adequate (1) 9
Haanen [26] Adequate (2) Reported (1) Partial (1) Inadequate (0) Inadequate (0) Inadequate (0) 4
Menziers [27] Adequate (2) Reported (1) Adequate (2) Adequate (2) Inadequate (0) Adequate (1) 8
Rucco [28] Inadequate (0) Not reported (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) 0
* Data provided on request
Table 4 Methodological quality of studies with guided imagery/hypnosis in FMS
Author (Reference) Alvarez [23] Castel [24] Grøndhal [25] Haa-nen [26] Men-ziers [27] Rucco [28]
Sample criteria Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1) Inadequate (0)
Evidence that sample criteria were met Adequate (1) Adequate (1) Inadequate (0) Adequate (1) Adequate (1) Inadequate (0)
Report of attrition Adequate (2) Partial (1) Adequate (2) Adequate (2) Adequate (2) Partial (1)
Rates of attrition Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1)
Sample characteristics Adequate (1) Adequate (1) Inadequate (0) Adequate (1) Adequate (1) Adequate (1)
Group equivalence Adequate (1) Inadequate (0) Inadequate (0) Adequate (1) Adequate (1) Adequate (1)
Adequacy of randomisation Adequate (2)* Inadequate (0) Adequate (2)* Inadequate (0) Inadequate (0) Inadequate (0)
Concelament of treatment allocation Adequate (1)* Inadequate (0) Adequate (1)* Inadequate (0) Inadequate (0) Inadequate (0)
Blinding of assessor Adequate (1)* Inadequate (0) Adequate (1)* Inadequate (0) Inadequate (0) Inadequate (0)
Treat-ment expectations Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0)
Justifications of outcomes Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1)
Validity of outcomes for context Adequate (2) Adequate (2) Adequate (2) Adequate (2) Adequate (2) Adequate (2)
Reliability and sensitivity to change of outcomes Adequate (2) Adequate (2) Adequate (2) Adequate (2) Adequate (2) Adequate (2)
Follow up of at least 6 months Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0)
Power calculation Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0) Inadequate (0)
Sufficient sample size Inadequate (0) Adequate (1) Inadequate (0) Adequate (1) Adequate (1) Adequate (1)
Adequate data analysis Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1) Adequate (1)
Adequate reporting of summary statistics Adequate (1) Adequate (1) Adequate (1)* Adequate (1) Adequate (1) Inadequate (0)
Intention to treat analysis Inadequate (0) Inadequate (0) Inadequate (0) Adequate (1) Inadequate (0) Inadequate (0)
Control group Adequate (2) Adequate (2) Adequate (2) Adequate (2) Adequate (2) Inadequate (0)
Sum 20 14 17 17 16 10
* Data provided on request
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Page 8 of 11assumptions and therapeutic technics. But not all hyp-
nosis involves guided imagery, and guided imagery does
not necessarily result in a hypnotic state. The intended
subgroup analysis of hynosis and guided imagery was
not possible due to limited data.
In contrast to a recent Cochrane review on psycholo-
gical therapies in chronic pain [33] we included studies
with less than 10 participants in each study arm
because of the limited number of studies with hypno-
sis/guided imagery available. Metaregression demon-
strated no significant correlation between the
magnitude of effect size on pain at final treatment and
sample size. Thereforefore the positive effect on pain is
robust against small sample size in our analysis.
Although every effort was made to obtain missing data
on study design from authors, it was not possible in
every case to obtain them. Therefore the study quality
might be underestimated in some trials.
Some major risks of bias listed in Cochrane reviews
(adequacy of randomisation, concealment of treatment
allocation, blinding of the outcome assessor, ITT-analy-
sis) [10] were present in the majority of studies. Metare-
gression analysis demonstrated that the positive effect
on pain was associated with low methodological study
quality.
We substituted one missing SD despite the small sam-
ple sizes and substantial heterogeneity. Furthermore we
adjusted the outcomes posttreatment by baseline values
because of baseline differences of one study. We demon-
strated by sensitivity analyses that by removing these
two studies only a statistical trend (p < 0.1) of the effect
of hypnosis/guided imagery on pain at final treatment
was detectable.
There was significant between-study heterogeneity for
the outcome pain. To address this limitation we used a
random-effects model.
It should be emphasized that all analyses might be
underpowered due to the limited number of studies.
Adverse events were not reported. Therefore no defi-
nitive statement on the safety of hypnosis/guided ima-
gery in FMS is possible.
Responses in studies with chronic pain patients are
frequently not Gaussian, but with a split between
responders and non-responders. No study assessed
Pain  final treatment 
 
Study or Subgroup
Alvarez HT 2007
Castel CBT plus HT 2009
Grondahl HT 2008
Haanen HT 1991
Menzies GI 2006
Rucco HT 1995
Total (95% CI)
Heterogeneity: Tau² = 1.45; Chi² = 42.16, df = 5 (P < 0.00001); I² = 88%
Test for overall effect: Z = 2.20 (P = 0.03)
Mean
57.7
5.8
3.8
6
5.1
0.6
SD
43.7
2.1
2.2
2.2
0.5
1.5
Total
7
16
7
20
24
24
98
Mean
46
6.1
3.8
9.3
5.8
6.9
SD
36.2
2.5
2.3
2.1
0.4
1.3
Total
4
16
5
20
24
11
80
Weight
15.3%
17.9%
15.8%
17.9%
18.1%
15.1%
100.0%
IV, Random, 95% CI
0.26 [-0.98, 1.49]
-0.13 [-0.82, 0.57]
0.00 [-1.15, 1.15]
-1.50 [-2.21, -0.79]
-1.52 [-2.17, -0.87]
-4.27 [-5.55, -2.99]
-1.17 [-2.21, -0.13]
Hypnosis/guided imagery Controls Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours experimental Favours control
    
Quality of life final treatment 
 
Study or Subgroup
Alvarez HT 2007
Castel CBT plus HT 2009
Menzies GI 2006
Total (95% CI)
Heterogeneity: Tau² = 1.93; Chi² = 22.19, df = 2 (P < 0.0001); I² = 91%
Test for overall effect: Z = 1.06 (P = 0.29)
Mean
45.9
48
40.5
SD
30.3
19.5
3.3
Total
7
16
24
47
Mean
29.2
61
48.8
SD
25.7
22.7
3.2
Total
5
16
24
45
Weight
31.2%
34.6%
34.2%
100.0%
IV, Random, 95% CI
0.54 [-0.64, 1.72]
-0.60 [-1.31, 0.11]
-2.51 [-3.28, -1.74]
-0.90 [-2.55, 0.76]
Hypnosis/guided imagery Controls Std. Mean Difference Std. Mean Difference
IV, Random, 95% CI
-4 -2 0 2 4
Favours experimental Favours control  
 
Legend: CBT= cognitive -behavioral therapy; CI= Confidence Interval; GI = guided 
imagery; HT=Hypnosis; IV= inverse variance 
Figure 2 Forest plots of the effect estimates (standardised
mean differences) of hypnosis/guided imagery versus controls
on outcomes at final treatment.
Table 5 Effect sizes of hypnosis/guided imagery on selected outcome variables
Outcome title Number of
studies
Number of
patients
Effect size (SMD [95%
CI])
Test for overall effect p-
value
Heterogeneity I² [%];
Tau²
Final treat-ment
01 Pain 6 178 -1.17 [-2.21, -0.13] 0.03 88; 1.45
02 Fatigue 1 12 Not calculated
03 Sleep 2 66 Not calculated
04 Depressed
mood
1 12 Not calculated
05 HRQOL 3 92 -0.90 [-2.55, 0.76] 0.29 91; 1.93
Follow up
01 Pain 2 88 Not calculated *
02 Fatigue 1 40 Not calculated
03 Sleep 1 40 Not calculated
04 Depressed
mood
00
05 HRQOL 1 48 Not calculated
Abbreviations: HRQOL: Health-related quality of life; SMD: Standardised mean difference; CI: Confidence interval
* Standard deviation of one study not available
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Page 9 of 11predefined response rates (e.g. 30% pain reduction).
Therefore IMMPACT response outcomes [34] could not
be calculated.
Conclusions
Implications for clinical practice
Because of the methodological limitations of the studies
with hypnosis/guided imagery outlined above we cannot
fully recommend hypnosis/guided imagery for FMS
therapy. The use of hypnosis/guided imagery as an
adjunct to efficacious pharmacological and non-pharma-
cological treatments had been recommended by the
German interdisciplinary guideline on FMS based on
expert consensus [31]. Regular home training by audio-
tapes with hypnotic suggestions and guided imaginations
could be useful.
Implications for research
Further studies with multi-site recruitment producing
adequate sample sizes are necessary to allow for stron-
ger tests of treatment efficacy and for examination of
individual (e.g. gender, age, hypnotisability) differences
in treatment response. Moreover the appropriate meth-
ods (live or audiotape therapy or combination of both
types) and the optimal dosage need to be determined.
Predictors of positive treatment outcomes, e.g. suggest-
ibility and treatment expectations, should be explored
[32].
The methodological quality of further studies could be
improved by the following issues: The key domains of
F M Ss h o u l db ea s s e s s e db yac o r es e to fo u t c o m em e a -
sures. Response rates should be measured [34]. Recom-
mendations on the quality of the treatment delivered
and study design should be followed [13].
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